Condition
High Grade Meningioma
Total Trials
4
Recruiting
0
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
P 2 (1)
P 3 (1)
Trial Status
Active Not Recruiting1
Unknown1
Completed1
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT03251989CompletedPrimary
Rare CNS Tumors Outcomes &Risk
NCT03279692Phase 2Active Not RecruitingPrimary
Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma
NCT07613450Phase 3Not Yet RecruitingPrimary
A Phase III Study of SYHA1813 for Recurrent or Progressive High-Grade Meningiomas
NCT05630664Unknown
Liquid Biopsy in High-grade Gliomas and Meningiomas
Showing all 4 trials